1. Home
  2. CHW vs DCTH Comparison

CHW vs DCTH Comparison

Compare CHW & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Global Dynamic Income Fund

CHW

Calamos Global Dynamic Income Fund

HOLD

Current Price

$8.24

Market Cap

527.5M

Sector

Finance

ML Signal

HOLD

DCTH

Delcath Systems Inc.

HOLD

Current Price

$15.65

Market Cap

578.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHW
DCTH
Founded
N/A
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
527.5M
578.4M
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
CHW
DCTH
Price
$8.24
$15.65
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $22.00
AVG Volume (30 Days)
139.4K
★ 327.8K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 107.53
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
$24.54
Revenue Next Year
N/A
$33.15
P/E Ratio
★ N/A
$402.00
Revenue Growth
N/A
N/A
52 Week Low
$6.98
$8.12
52 Week High
$9.18
$17.42

Technical Indicators

Market Signals
Indicator
CHW
DCTH
Relative Strength Index (RSI) 43.52 44.61
Support Level $7.90 $9.98
Resistance Level $8.27 $16.51
Average True Range (ATR) 0.15 0.45
MACD -0.00 -0.13
Stochastic Oscillator 36.07 10.39

Price Performance

Historical Comparison
CHW
DCTH

About CHW Calamos Global Dynamic Income Fund

Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities, and alternative investments.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: